全球消除HBV母婴传播的进展与挑战

郑洪巧; 王爱玲

doi:10.12449/JCH241104

全球消除HBV母婴传播的进展与挑战

DOI: 10.12449/JCH241104

郑洪巧¹,
王爱玲^2, , ,

1.
中国疾病预防控制中心，北京 102206
2.
国家卫生健康委妇幼健康中心，北京 100081

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：郑洪巧负责文章撰写；王爱玲负责拟定写作思路，指导文章撰写，修改论文并最后定稿。

详细信息

通信作者:
王爱玲， ailing@chinawch.org.cn （ORCID： 0000-0003-4801-6186）

计量
- 文章访问数: 134
- HTML全文浏览量: 1310
- PDF下载量: 49
- 被引次数: 0
出版历程
- 收稿日期: 2024-09-13
- 录用日期: 2024-10-11
- 出版日期: 2024-11-25

Advances and challenges in eliminating mother-to-child transmission of hepatitis B virus worldwide

Hongqiao ZHENG¹,
Ailing WANG^{2
, ,
,}

1.
Chinese Center for Disease Control and Prevention，Beijing 102206，China
2.
National Center for Women and Children’s Health，NHC，PRC，Beijing 100081，China

More Information

Corresponding author: Wang Ailing， ailing@chinawch.org.cn （ORCID： 0000-0003-4801-6186）

摘要

摘要: 目前，全球89.8%的国家和地区有孕产妇乙型肝炎检测的政策。2022年，全球乙型肝炎疫苗出生接种率、第3剂接种率分别为45%、85%，约3%高病毒载量孕产妇接受了抗病毒治疗，5岁及以下儿童乙型肝炎表面抗原流行率约为0.7%。全球各国乙型肝炎母婴传播取得阶段性进展，但进展差异较大，且面临诸多挑战。全球各地乙型肝炎流行情况、疫苗接种情况、抗病毒药物获取情况不同，此外，实验室检测能力不足、感染孕产妇难以持续获得治疗干预等因素均对消除HBV母婴传播造成了阻碍。
- 乙型肝炎病毒 /
- 传染性疾病传播，垂直 /
- 疾病消除
Abstract: At present， there are policies for hepatitis B testing in 89.8% of countries and regions around the world. In 2022， the global hepatitis B vaccine birth dose coverage reached 45%， while the third-dose coverage reached 85%. Approximately 3% of pregnant women with high viral loads have received antiviral therapy， and the prevalence rate of HBsAg is about 0.7% among children aged≤5 years. While significant progress has been made in various countries towards eliminating mother-to-child transmission of hepatitis B virus （HBV）， there are still large gaps across countries and numerous challenges. There are differences in the prevalence of hepatitis B， vaccination， and access to antiviral drugs across the globe， and in addition， the factors such as insufficient laboratory testing capacity and difficulties in ensuring sustained access to treatment among pregnant and parturient women with HBV infection pose obstacles to eliminating the mother-to-child transmission of HBV.
- Hepatitis B Virus /
- Infectious Disease Transmission， Vertical /
- Disease Eradication

HTML全文

参考文献(45)

[1]	World Health Organization. Hepatitis B[EB/OL].( 2024-04-09)[ 2024-09-21]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
[2]	THIO CL, GUO N, XIE C, et al. Global elimination of mother-to-child transmission of hepatitis B: Revisiting the current strategy[J]. Lancet Infect Dis, 2015, 15( 8): 981- 985. DOI: 10.1016/S1473-3099(15)00158-9.
[3]	Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8( 10): 879- 907. DOI: 10.1016/S2468-1253(23)00197-8.
[4]	KFUTWAH AK, TEJIOKEM MC, NJOUOM R. A low proportion of HBeAg among HBsAg-positive pregnant women with known HIV status could suggest low perinatal transmission of HBV in Cameroon[J]. Virol J, 2012, 9: 62. DOI: 10.1186/1743-422X-9-62.
[5]	RAMOS JM, TORO C, REYES F, et al. Seroprevalence of HIV-1, HBV, HTLV-1 and Treponema pallidum among pregnant women in a rural hospital in Southern Ethiopia[J]. J Clin Virol, 2011, 51( 1): 83- 85. DOI: 10.1016/j.jcv.2011.01.010.
[6]	WANG XY, LIU J, WANG Q, et al. Economic-related inequalities in hepatitis B virus infection among 115.8 million pregnant women in China from 2013 to 2020[J]. EClinicalMedicine, 2022, 49: 101465. DOI: 10.1016/j.eclinm.2022.101465.
[7]	NARTEY YA, OKINE R, SEAKE-KWAWU A, et al. A nationwide cross-sectional review of in-hospital hepatitis B virus testing and disease burden estimation in Ghana, 2016-2021[J]. BMC Public Health, 2022, 22( 1): 2149. DOI: 10.1186/s12889-022-14618-3.
[8]	E B, KO K, KIM R, et al. Residual risk of mother-to-child transmission of HBV despite timely hepatitis B vaccination: A major challenge to eliminate hepatitis B infection in Cambodia[J]. BMC Infect Dis, 2023, 23( 1): 261. DOI: 10.1186/s12879-023-08249-1.
[9]	PORNGASEMSART Y, SIRILERT S, TONGSONG T. Change in prevalence of hepatitis B virus infection in pregnant women in the last two decades in Thailand[J]. Viruses, 2024, 16( 2): 314. DOI: 10.3390/v16020314.
[10]	BAILEY H, NASTOULI E, WEBB S, et al. Characteristics, treatment and care of pregnant women living with hepatitis B in England: Findings from a national audit[J]. Epidemiol Infect, 2023, 151: e50. DOI: 10.1017/S0950268823000225.
[11]	Pan American Health Organization. EMTCT Plus: Framework for elimination of mother-to-child transmission of HIV, Syphilis, Hepatitis B, and Chagas[EB/OL].[ 2024-10-25]. https://iris.paho.org/bitstream/handle/10665.2/34306/PAHOCHA17009-eng.pdf?sequence=1&isAllowed=y. https://iris.paho.org/bitstream/handle/10665.2/34306/PAHOCHA17009-eng.pdf?sequence=1&isAllowed=y
[12]	World Health Organization Regional Office for the Western Pacific. Regional framework for the triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis in Asia and the Pacific, 2018-2030[R]. Manila: WHO Regional Office for the Western Pacific, 2018.
[13]	World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy[R/OL].( 2020-12-27)[ 2024-09-21]. https://www.who.int/publications/i/item/978-92-4-000270-8. https://www.who.int/publications/i/item/978-92-4-000270-8
[14]	World Health Organization. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus[R]. Geneva: World Health Organization, 2021.
[15]	World Health Organization. Viral hepatitis B and C burden of disease, policy adoption and implementation status in WHO regions, 2024[EB/OL].[ 2024-10-25]. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/j0482-who-ias-hep_factsheet_v3.pdf. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/j0482-who-ias-hep_factsheet_v3.pdf
[16]	Department of Maternal and Child Health, National Health Commission of the People’s Republic of China. Notice of the General Office of the National Health Commission on the issuance of work norms for the prevention of mother-to-child transmission of HIV, syphilis and hepatitis B(2020 edition)[EB/OL].( 2020-11-25)[ 2024-09-21]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml 国家卫生健康委员会妇幼健康司. 国家卫生健康委办公厅关于印发预防艾滋病、梅毒和乙肝母婴传播工作规范(2020年版)的通知[EB/OL].( 2020-11-25)[ 2024-09-21]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml
[17]	OLAKUNDE BO, ADEYINKA DA, NDUKWE CD, et al. Antenatal hepatitis B screening in Nigeria: A comparative analysis with syphilis and HIV[J]. Int J STD AIDS, 2021, 32( 14): 1290- 1297. DOI: 10.1177/09564624211035922.
[18]	World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017-Recommendations[J]. Vaccine, 2019, 37( 2): 223- 225. DOI: 10.1016/j.vaccine.2017.07.046.
[19]	NGUYEN HT, THAVORNCHAROENSAP M, PHUNG TL, et al. Comparative efficacy and safety of pharmacologic interventions to prevent mother-to-child transmission of hepatitis B virus: A systematic review and network meta-analysis[J]. Am J Obstet Gynecol, 2022, 227( 2): 163- 172. DOI: 10.1016/j.ajog.2022.02.042.
[20]	DING ZR, KANG WY, LU L, et al. Evaluation on the efficacy of prevention programs and relevant factors targeting mother-to-infant transmission on hepatitis B virus in Yunnan province[J]. Chin J Epidemiol, 2014, 35( 2): 114- 116. DOI: 10.3760/cma.j.issn.0254-6450.2014.02.002. 丁峥嵘, 康文玉, 陆林, 等. 云南省乙型肝炎母婴阻断实施效果评价[J]. 中华流行病学杂志, 2014, 35( 2): 114- 116. DOI: 10.3760/cma.j.issn.0254-6450.2014.02.002.
[21]	WANG H, FANG JW, GU ZW, et al. Application of hepatitis B immunoglobulin in prevention of mother-to-child transmission of chronic hepatitis B in HBsAg- and HBeAg-positive mother[J]. J Obstet Gynaecol, 2022, 42( 5): 877- 882. DOI: 10.1080/01443615.2021.1946495.
[22]	World Health Organization. Hepatitis B(HepB3) immunization coverage among 1-year-olds(%)[EB/OL].[ 2024-09-21]. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hepatitis-b-(hepb3)-immunization-coverage-among-1-year-olds-(-). https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hepatitis-b-(hepb3)-immunization-coverage-among-1-year-olds-(-)
[23]	World Health Organization. Only 45% of babies received the hepatitis B vaccine within 24 hours of birth in 2022.[EB/OL].( 2024-04-09)[ 2024-09-21]. https://www.who.int/multi-media/details/only-45percent-of-babies-received-the-hepatitis-b-vaccine-within-24-hours-of-birth-in-2022. https://www.who.int/multi-media/details/only-45percent-of-babies-received-the-hepatitis-b-vaccine-within-24-hours-of-birth-in-2022
[24]	World Health Organization. Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022- 2030: Report on progress and gaps 2024, second edition[EB/OL].( 2024-07-22)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240097872. https://www.who.int/publications/i/item/9789240097872
[25]	ZHANG BF, CHENG ML, ZHANG Q, et al. Clinical study on blocking mother-to-child transmission of hepatitis B virus with high viral load and HBeAg positivity during pregnancy in Guizhou province[J]. Chin J Hepatol, 2018, 26( 12): 945- 950. DOI: 10.3760/cma.j.issn.1007-3418.2018.12.013. 张宝芳, 程明亮, 张权, 等. 贵州地区HBeAg阳性乙型肝炎病毒高载量孕妇母婴阻断的临床研究[J]. 中华肝脏病杂志, 2018, 26( 12): 945- 950. DOI: 10.3760/cma.j.issn.1007-3418.2018.12.013.
[26]	YI W, CAO XZ, ZENG Z, et al. Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: A prospective study with 3-year follow-up[J]. Virulence, 2021, 12( 1): 1527- 1537. DOI: 10.1080/21505594.2021.1936769.
[27]	ZHU B, LV XJ, ZHAO ZY, et al. Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus[J]. Medicine(Baltimore), 2021, 100( 44): e27695. DOI: 10.1097/MD.0000000000027695.
[28]	WANG M, RAN R, ZHU YX, et al. Comparison of tenofovir disoproxil fumarate and telbivudine in preventing hepatitis B transmission in mothers with high viral load[J]. Int J Gynaecol Obstet, 2023, 160( 2): 646- 652. DOI: 10.1002/ijgo.14341.
[29]	ZHENG H, ZHANG GM, CHAN PL, et al. Compliance among infants exposed to hepatitis B virus in a post-vaccination serological testing program in four provinces in China[J]. Infect Dis Poverty, 2019, 8( 1): 57. DOI: 10.1186/s40249-019-0568-y.
[30]	World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[EB/OL].( 2024-03-29)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240090903. https://www.who.int/publications/i/item/9789240090903
[31]	Infectious Diseases Physicians Branch, Chinese Medical Doctor Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Chinese practice guideline for the prevention and treatment of mother-to-child transmission of hepatitis B virus(version 2024)[J]. J Clin Hepatol, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809. 中国医师协会感染科医师分会, 中华医学会感染病学分会. 中国乙型肝炎病毒母婴传播防治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809.
[32]	GUO HJ, GAO YF, LIU HY, et al. Impact of cessation of antiviral therapy at delivery on postpartum liver function in mothers with chronic hepatitis B virus infection[J]. Chin J Hepatol, 2019, 27( 2): 112- 117. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.008. 郭辉杰, 高云飞, 刘惠媛, 等. 妊娠期抗病毒治疗的慢性乙型肝炎病毒感染孕妇分娩时停药对产后肝功能的影响[J]. 中华肝脏病杂志, 2019, 27( 2): 112- 117. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.008.
[33]	World Health Organization. Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections for the period 2022- 2030[EB/OL].( 2022-07-18)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240053779. https://www.who.int/publications/i/item/9789240053779
[34]	CUI FQ, SHEN LP, LI L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23( 5): 765- 772. DOI: 10.3201/eid2305.161477.
[35]	YIN XR, WANG W, CHEN H, et al. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China[J]. Nat Med, 2024, 30( 2): 455- 462. DOI: 10.1038/s41591-023-02782-x.
[36]	WANG AL, QIAO YP, DOU LX, et al. Challenges of eliminating mother-to-child transmission of HIV, syphilis and hepatitis B in China: A cross-sectional survey[J]. Lancet, 2018, 392: S55. DOI: 10.1016/S0140-6736(18)32684-9.
[37]	World Health Organization. Guidance for country validation of viral hepatitis elimination and path to elimination[EB/OL].( 2023-10-05)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240078635. https://www.who.int/publications/i/item/9789240078635
[38]	ZHENG H, WANG FZ, ZHANG GM, et al. Cost-benefit analysis of the hepatitis B vaccination to prevent mother-to-child transmission strategies in China, 1992-2019[J]. Chin J Epidemiol, 2021, 42( 9): 1537- 1545. DOI: 10.3760/cma.j.cn112338-20210319-00226. 郑徽, 王富珍, 张国民, 等. 中国1992—2019年乙型肝炎疫苗免疫及母婴阻断策略的成本效益分析[J]. 中华流行病学杂志, 2021, 42( 9): 1537- 1545. DOI: 10.3760/cma.j.cn112338-20210319-00226.
[39]	WANG AL, SUN H, WANG Q, et al. Challenges and prospects of eliminating AIDS, syphilis and mother-to-child transmission of hepatitis B in China[J]. Chin J AIDS STD, 2023, 29( 8): 845- 847. DOI: 10.13419/j.cnki.aids.2023.08.01. 王爱玲, 孙贺, 王前, 等. 中国消除艾滋病梅毒和乙肝母婴传播的挑战与展望[J]. 中国艾滋病性病, 2023, 29( 8): 845- 847. DOI: 10.13419/j.cnki.aids.2023.08.01.
[40]	PATTON H, TRAN TT. Management of hepatitis B during pregnancy[J]. Nat Rev Gastroenterol Hepatol, 2014, 11( 7): 402- 409. DOI: 10.1038/nrgastro.2014.30.
[41]	ZHOU LY, LIU XT, OU XT, et al. Chronic hepatitis B in women of childbearing age and pregnant women in China: A cross-sectional study[J]. Am J Trop Med Hyg, 2024, 110( 4): 719- 723. DOI: 10.4269/ajtmh.23-0217.
[42]	BOUCHERON P, LU Y, YOSHIDA K, et al. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: A systematic review and meta-analysis[J]. Lancet Infect Dis, 2021, 21( 1): 85- 96. DOI: 10.1016/S1473-3099(20)30593-4.
[43]	CHALID MT, TURYADI, SI IE, et al. A cautionary note to hepatitis B e antigen(HBeAg)-negative test results in pregnant women in an area prevalent of HBeAg-negative chronic hepatitis B[J]. J Med Virol, 2023, 95( 1): e28125. DOI: 10.1002/jmv.28125.
[44]	PLATT L, FRENCH CE, CR McGOWAN et al. Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis[J]. J Viral Hepat, 2020, 27( 3): 294- 315. DOI: 10.1111/jvh.13217.
[45]	World Health Organization. Criteria for validation of elimination of viral hepatitis B and C: report of 7 country pilots[EB/OL].( 2022-09-01)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240055292. https://www.who.int/publications/i/item/9789240055292